| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 73 | 2021 | 1144 | 10.510 |
Why?
|
| Ischemic Attack, Transient | 14 | 2019 | 91 | 4.970 |
Why?
|
| Brain Ischemia | 26 | 2020 | 402 | 4.000 |
Why?
|
| Fibrinolytic Agents | 15 | 2020 | 165 | 2.370 |
Why?
|
| Tissue Plasminogen Activator | 16 | 2020 | 125 | 2.180 |
Why?
|
| Thrombolytic Therapy | 11 | 2020 | 182 | 1.580 |
Why?
|
| Cerebral Hemorrhage | 8 | 2021 | 89 | 1.500 |
Why?
|
| Atrial Fibrillation | 11 | 2020 | 801 | 1.420 |
Why?
|
| Stroke Rehabilitation | 5 | 2021 | 46 | 1.320 |
Why?
|
| Brain | 14 | 2024 | 1493 | 1.310 |
Why?
|
| Humans | 109 | 2025 | 60132 | 1.190 |
Why?
|
| Secondary Prevention | 4 | 2017 | 154 | 1.110 |
Why?
|
| Middle Cerebral Artery | 4 | 2017 | 46 | 1.100 |
Why?
|
| Hypertension | 8 | 2017 | 603 | 1.060 |
Why?
|
| Aged | 50 | 2021 | 13581 | 1.000 |
Why?
|
| Thrombectomy | 2 | 2019 | 207 | 1.000 |
Why?
|
| Antihypertensive Agents | 4 | 2016 | 173 | 0.940 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 11 | 0.920 |
Why?
|
| Cerebrovascular Disorders | 4 | 2018 | 74 | 0.910 |
Why?
|
| Organoids | 1 | 2024 | 41 | 0.890 |
Why?
|
| Female | 62 | 2021 | 31250 | 0.890 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2014 | 218 | 0.880 |
Why?
|
| Motor Neuron Disease | 1 | 2023 | 29 | 0.840 |
Why?
|
| Male | 56 | 2021 | 27971 | 0.830 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2016 | 8 | 0.800 |
Why?
|
| Hematoma | 3 | 2019 | 74 | 0.790 |
Why?
|
| Blood Pressure | 3 | 2016 | 522 | 0.740 |
Why?
|
| Middle Aged | 46 | 2021 | 16535 | 0.740 |
Why?
|
| Endovascular Procedures | 3 | 2016 | 581 | 0.720 |
Why?
|
| Treatment Outcome | 28 | 2020 | 5262 | 0.720 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 251 | 0.690 |
Why?
|
| Bed Rest | 1 | 2019 | 10 | 0.670 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 5197 | 0.670 |
Why?
|
| Myxoma | 1 | 2019 | 14 | 0.670 |
Why?
|
| Risk Factors | 25 | 2020 | 5082 | 0.660 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2016 | 1481 | 0.650 |
Why?
|
| Severity of Illness Index | 13 | 2019 | 1471 | 0.640 |
Why?
|
| Time Factors | 22 | 2020 | 3618 | 0.630 |
Why?
|
| Retrospective Studies | 22 | 2020 | 6139 | 0.630 |
Why?
|
| Piperazines | 3 | 2025 | 81 | 0.630 |
Why?
|
| Carotid Stenosis | 4 | 2014 | 105 | 0.620 |
Why?
|
| Telemedicine | 2 | 2023 | 336 | 0.610 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2017 | 41 | 0.600 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2017 | 72 | 0.590 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2021 | 2049 | 0.580 |
Why?
|
| Concurrent Review | 1 | 2017 | 3 | 0.570 |
Why?
|
| Length of Stay | 4 | 2020 | 781 | 0.560 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 1039 | 0.560 |
Why?
|
| Triage | 2 | 2016 | 111 | 0.560 |
Why?
|
| Ticlopidine | 2 | 2014 | 47 | 0.550 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 30 | 0.540 |
Why?
|
| Teaching | 2 | 2008 | 157 | 0.530 |
Why?
|
| Virtual Reality | 1 | 2016 | 12 | 0.530 |
Why?
|
| Thalamic Diseases | 1 | 2016 | 2 | 0.520 |
Why?
|
| Primary Prevention | 1 | 2017 | 137 | 0.520 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2016 | 24 | 0.510 |
Why?
|
| Aspirin | 2 | 2014 | 171 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 719 | 0.490 |
Why?
|
| Postmenopause | 4 | 2021 | 246 | 0.470 |
Why?
|
| Feedback, Psychological | 1 | 2014 | 12 | 0.460 |
Why?
|
| Quality of Health Care | 2 | 2020 | 524 | 0.460 |
Why?
|
| Occupational Therapy | 1 | 2014 | 12 | 0.460 |
Why?
|
| Speech Therapy | 1 | 2014 | 15 | 0.460 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 45 | 0.450 |
Why?
|
| Dipyridamole | 1 | 2013 | 17 | 0.450 |
Why?
|
| Smoking | 4 | 2018 | 835 | 0.440 |
Why?
|
| Endarterectomy, Carotid | 2 | 2012 | 87 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 737 | 0.430 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 332 | 0.430 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2013 | 13 | 0.420 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 133 | 0.420 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 191 | 0.420 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 203 | 0.410 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2012 | 4 | 0.410 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2012 | 2 | 0.410 |
Why?
|
| Cocaine-Related Disorders | 1 | 2013 | 76 | 0.410 |
Why?
|
| Intracranial Aneurysm | 1 | 2016 | 344 | 0.400 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 7 | 2020 | 141 | 0.400 |
Why?
|
| Intracranial Hemorrhages | 3 | 2020 | 62 | 0.400 |
Why?
|
| Quality Improvement | 1 | 2017 | 428 | 0.400 |
Why?
|
| Sulfones | 2 | 2009 | 37 | 0.400 |
Why?
|
| Recovery of Function | 7 | 2020 | 267 | 0.390 |
Why?
|
| Hospital Units | 1 | 2011 | 8 | 0.390 |
Why?
|
| Cohort Studies | 7 | 2019 | 2479 | 0.380 |
Why?
|
| Leukoaraiosis | 3 | 2019 | 45 | 0.380 |
Why?
|
| Brain Damage, Chronic | 1 | 2011 | 5 | 0.370 |
Why?
|
| Inpatients | 1 | 2014 | 300 | 0.370 |
Why?
|
| Colonoscopy | 1 | 2012 | 104 | 0.370 |
Why?
|
| Hospitals | 1 | 2014 | 377 | 0.370 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2012 | 24 | 0.360 |
Why?
|
| Stents | 2 | 2013 | 459 | 0.360 |
Why?
|
| Internship and Residency | 2 | 2008 | 747 | 0.340 |
Why?
|
| Educational Measurement | 2 | 2008 | 213 | 0.330 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 253 | 0.330 |
Why?
|
| Neurology | 3 | 2020 | 35 | 0.330 |
Why?
|
| Troponin | 2 | 2019 | 37 | 0.320 |
Why?
|
| Anticoagulants | 4 | 2019 | 488 | 0.320 |
Why?
|
| Prognosis | 7 | 2020 | 1591 | 0.310 |
Why?
|
| Mortality | 2 | 2021 | 165 | 0.310 |
Why?
|
| Neurophysiology | 1 | 2008 | 7 | 0.300 |
Why?
|
| Clinical Medicine | 1 | 2008 | 16 | 0.300 |
Why?
|
| Video Games | 1 | 2008 | 12 | 0.300 |
Why?
|
| Embolism, Paradoxical | 1 | 2008 | 14 | 0.300 |
Why?
|
| Foramen Ovale, Patent | 1 | 2008 | 13 | 0.300 |
Why?
|
| Mass Screening | 1 | 2013 | 662 | 0.290 |
Why?
|
| Intracranial Embolism | 3 | 2017 | 39 | 0.280 |
Why?
|
| Recurrence | 4 | 2016 | 600 | 0.280 |
Why?
|
| Young Adult | 6 | 2019 | 4396 | 0.280 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2007 | 29 | 0.280 |
Why?
|
| Spinal Puncture | 1 | 2007 | 13 | 0.280 |
Why?
|
| Acute Disease | 3 | 2014 | 661 | 0.280 |
Why?
|
| Whole Genome Sequencing | 2 | 2024 | 63 | 0.270 |
Why?
|
| Brain Stem Infarctions | 1 | 2006 | 4 | 0.260 |
Why?
|
| Needles | 1 | 2007 | 66 | 0.260 |
Why?
|
| Pons | 1 | 2006 | 15 | 0.260 |
Why?
|
| Quadriplegia | 1 | 2006 | 14 | 0.260 |
Why?
|
| Nanotubes, Carbon | 1 | 2016 | 22 | 0.260 |
Why?
|
| Smoking Cessation | 3 | 2018 | 538 | 0.260 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2007 | 52 | 0.260 |
Why?
|
| Nanofibers | 1 | 2016 | 20 | 0.260 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2016 | 181 | 0.260 |
Why?
|
| Age Factors | 6 | 2020 | 1525 | 0.260 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 264 | 0.260 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1035 | 0.260 |
Why?
|
| Air Pollutants, Occupational | 1 | 2016 | 76 | 0.260 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2016 | 21 | 0.250 |
Why?
|
| Piracetam | 1 | 2005 | 8 | 0.250 |
Why?
|
| Hyponatremia | 1 | 2005 | 12 | 0.250 |
Why?
|
| Logistic Models | 7 | 2018 | 1259 | 0.240 |
Why?
|
| Pandemics | 4 | 2023 | 629 | 0.240 |
Why?
|
| Hospitalization | 4 | 2020 | 1302 | 0.240 |
Why?
|
| Anticonvulsants | 1 | 2005 | 95 | 0.230 |
Why?
|
| Clinical Protocols | 1 | 2005 | 137 | 0.230 |
Why?
|
| Thalamus | 2 | 2016 | 65 | 0.230 |
Why?
|
| Curriculum | 1 | 2008 | 570 | 0.230 |
Why?
|
| Betacoronavirus | 3 | 2020 | 164 | 0.230 |
Why?
|
| Epilepsy | 1 | 2005 | 111 | 0.220 |
Why?
|
| Hypercholesterolemia | 2 | 2014 | 68 | 0.220 |
Why?
|
| Heart Atria | 2 | 2017 | 138 | 0.220 |
Why?
|
| Cerebral Angiography | 4 | 2017 | 283 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 310 | 0.210 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 277 | 0.210 |
Why?
|
| Adult | 13 | 2019 | 15985 | 0.200 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 2 | 2020 | 7 | 0.200 |
Why?
|
| Ischemia | 2 | 2019 | 195 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 9 | 0.200 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 30 | 0.200 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 215 | 0.190 |
Why?
|
| United States | 10 | 2020 | 7622 | 0.190 |
Why?
|
| Rehabilitation Centers | 1 | 2021 | 12 | 0.190 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 62 | 0.190 |
Why?
|
| Biomarkers | 2 | 2024 | 1213 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 142 | 0.190 |
Why?
|
| Eggs | 1 | 2021 | 10 | 0.190 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 3 | 0.190 |
Why?
|
| Oxygen | 2 | 2014 | 309 | 0.190 |
Why?
|
| Genetic Loci | 1 | 2021 | 104 | 0.190 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 928 | 0.180 |
Why?
|
| Cholesterol, Dietary | 1 | 2021 | 29 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 443 | 0.180 |
Why?
|
| Incidence | 6 | 2020 | 1265 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 1 | 2021 | 84 | 0.180 |
Why?
|
| Myocardial Infarction | 3 | 2019 | 867 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2020 | 1937 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2021 | 105 | 0.180 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 16 | 0.170 |
Why?
|
| Databases, Factual | 4 | 2020 | 849 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 281 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2021 | 483 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2016 | 499 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 100 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 2 | 2011 | 303 | 0.170 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2009 | 25 | 0.170 |
Why?
|
| Retinal Artery Occlusion | 1 | 2019 | 5 | 0.170 |
Why?
|
| Cyclic GMP | 3 | 2009 | 28 | 0.160 |
Why?
|
| Thrombosis | 1 | 2002 | 190 | 0.160 |
Why?
|
| Vitamin K | 1 | 2019 | 17 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 33 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 647 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 454 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2021 | 3131 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 435 | 0.160 |
Why?
|
| Global Health | 1 | 2020 | 164 | 0.160 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 128 | 0.160 |
Why?
|
| Sweetening Agents | 1 | 2019 | 25 | 0.160 |
Why?
|
| Embolism | 1 | 2019 | 38 | 0.160 |
Why?
|
| Mechanical Thrombolysis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 24 | 0.160 |
Why?
|
| Spinal Cord | 2 | 2016 | 197 | 0.150 |
Why?
|
| Women's Health | 2 | 2019 | 390 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 105 | 0.150 |
Why?
|
| Sex Factors | 3 | 2019 | 969 | 0.150 |
Why?
|
| Beverages | 1 | 2019 | 65 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1100 | 0.150 |
Why?
|
| Sildenafil Citrate | 2 | 2009 | 9 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2016 | 92 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 301 | 0.150 |
Why?
|
| Purines | 2 | 2009 | 38 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 677 | 0.150 |
Why?
|
| Rhode Island | 2 | 2016 | 99 | 0.140 |
Why?
|
| White Matter | 1 | 2019 | 114 | 0.140 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 6 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 807 | 0.140 |
Why?
|
| Functional Laterality | 2 | 2016 | 133 | 0.140 |
Why?
|
| Radiography | 2 | 2019 | 514 | 0.140 |
Why?
|
| Weight Gain | 1 | 2018 | 163 | 0.140 |
Why?
|
| Demyelinating Diseases | 1 | 1997 | 15 | 0.140 |
Why?
|
| Vacuoles | 1 | 1997 | 27 | 0.140 |
Why?
|
| Atrial Function, Right | 1 | 2017 | 1 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 160 | 0.140 |
Why?
|
| Telemetry | 1 | 2017 | 21 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 42 | 0.140 |
Why?
|
| Hospital Mortality | 5 | 2020 | 855 | 0.140 |
Why?
|
| Atrial Flutter | 1 | 2017 | 20 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2616 | 0.140 |
Why?
|
| Hospital Administration | 1 | 2017 | 41 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 85 | 0.140 |
Why?
|
| Headache Disorders, Primary | 1 | 2016 | 4 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2018 | 323 | 0.140 |
Why?
|
| Alcohol Abstinence | 1 | 2016 | 11 | 0.140 |
Why?
|
| Disability Evaluation | 4 | 2019 | 217 | 0.140 |
Why?
|
| Random Allocation | 1 | 2017 | 197 | 0.130 |
Why?
|
| Spinal Cord Diseases | 1 | 1997 | 39 | 0.130 |
Why?
|
| Vasospasm, Intracranial | 1 | 2016 | 25 | 0.130 |
Why?
|
| Brain Diseases | 1 | 1997 | 68 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 206 | 0.130 |
Why?
|
| Dura Mater | 1 | 2016 | 35 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2018 | 147 | 0.130 |
Why?
|
| Motor Activity | 1 | 2019 | 343 | 0.130 |
Why?
|
| Carbolines | 2 | 2025 | 8 | 0.130 |
Why?
|
| Systole | 1 | 2016 | 110 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 424 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2018 | 161 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 102 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2016 | 131 | 0.120 |
Why?
|
| Registries | 5 | 2020 | 809 | 0.120 |
Why?
|
| Heart Rate | 1 | 2017 | 308 | 0.120 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 116 | 0.120 |
Why?
|
| Aneurysm, Ruptured | 1 | 2016 | 72 | 0.120 |
Why?
|
| Cerebral Infarction | 3 | 2016 | 75 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 466 | 0.120 |
Why?
|
| Decompressive Craniectomy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Brain Death | 1 | 2014 | 18 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 29 | 0.120 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 3 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 44 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2010 | 460 | 0.120 |
Why?
|
| Skull | 1 | 2014 | 57 | 0.120 |
Why?
|
| Neoplasms | 1 | 2025 | 1261 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2020 | 680 | 0.120 |
Why?
|
| Motion Therapy, Continuous Passive | 1 | 2014 | 1 | 0.120 |
Why?
|
| Odds Ratio | 4 | 2017 | 774 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2017 | 306 | 0.120 |
Why?
|
| Hospital Departments | 1 | 2014 | 13 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 213 | 0.120 |
Why?
|
| Adolescent | 3 | 2016 | 5958 | 0.110 |
Why?
|
| Comorbidity | 3 | 2020 | 1098 | 0.110 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2004 | 35 | 0.110 |
Why?
|
| Health Literacy | 1 | 2015 | 77 | 0.110 |
Why?
|
| Drainage | 1 | 2014 | 150 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 331 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2014 | 54 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 98 | 0.110 |
Why?
|
| Heart Failure | 2 | 2018 | 869 | 0.110 |
Why?
|
| Alcoholism | 1 | 2016 | 308 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 125 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 832 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 79 | 0.110 |
Why?
|
| Heparin | 1 | 2014 | 111 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2014 | 104 | 0.110 |
Why?
|
| Age of Onset | 1 | 2013 | 171 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 254 | 0.100 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2012 | 1 | 0.100 |
Why?
|
| Pupil Disorders | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dysarthria | 1 | 2012 | 8 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 157 | 0.100 |
Why?
|
| Apraxias | 1 | 2012 | 7 | 0.100 |
Why?
|
| Acyclovir | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 18 | 0.100 |
Why?
|
| Valine | 1 | 2012 | 30 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 314 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 71 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 201 | 0.100 |
Why?
|
| Prednisone | 1 | 2012 | 80 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2012 | 46 | 0.100 |
Why?
|
| Disease Progression | 2 | 2017 | 1054 | 0.100 |
Why?
|
| Risk | 2 | 2010 | 377 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2012 | 59 | 0.100 |
Why?
|
| Cerebral Arteries | 2 | 2009 | 39 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 910 | 0.090 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 170 | 0.090 |
Why?
|
| Retinal Vein | 1 | 2011 | 5 | 0.090 |
Why?
|
| Vision, Low | 1 | 2011 | 9 | 0.090 |
Why?
|
| Graves Disease | 1 | 2010 | 16 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 120 | 0.090 |
Why?
|
| Retinal Vein Occlusion | 1 | 2011 | 18 | 0.090 |
Why?
|
| Echocardiography | 3 | 2018 | 459 | 0.090 |
Why?
|
| Moyamoya Disease | 1 | 2010 | 11 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2010 | 34 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 679 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 165 | 0.090 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2020 | 28 | 0.090 |
Why?
|
| Prevalence | 2 | 2020 | 1300 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 157 | 0.090 |
Why?
|
| HIV Infections | 1 | 1997 | 927 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2012 | 272 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 743 | 0.080 |
Why?
|
| Life Style | 1 | 2011 | 330 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2012 | 317 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 858 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2009 | 61 | 0.080 |
Why?
|
| Lipoproteins, HDL | 1 | 2009 | 36 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2016 | 486 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 102 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2020 | 697 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 107 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2008 | 59 | 0.080 |
Why?
|
| Physical Examination | 1 | 2008 | 103 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 238 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 151 | 0.070 |
Why?
|
| Snoring | 1 | 2007 | 8 | 0.070 |
Why?
|
| Sleep Stages | 1 | 2007 | 16 | 0.070 |
Why?
|
| Neuropharmacology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Neuroanatomy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 171 | 0.070 |
Why?
|
| Group Processes | 1 | 2007 | 41 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2007 | 126 | 0.070 |
Why?
|
| Europe | 2 | 2017 | 184 | 0.070 |
Why?
|
| Polysomnography | 1 | 2007 | 54 | 0.070 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2006 | 3 | 0.070 |
Why?
|
| Polycarboxylate Cement | 1 | 2016 | 6 | 0.070 |
Why?
|
| Magnetoencephalography | 1 | 2006 | 7 | 0.070 |
Why?
|
| Recycling | 1 | 2016 | 7 | 0.070 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2006 | 8 | 0.070 |
Why?
|
| Manipulation, Chiropractic | 1 | 2006 | 5 | 0.070 |
Why?
|
| Vertebral Artery Dissection | 1 | 2006 | 14 | 0.070 |
Why?
|
| Dust | 1 | 2016 | 42 | 0.070 |
Why?
|
| Nerve Regeneration | 1 | 2006 | 31 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 75 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2006 | 30 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 1565 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2016 | 57 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 138 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1172 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 538 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2005 | 11 | 0.060 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2005 | 7 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2016 | 139 | 0.060 |
Why?
|
| Canada | 1 | 2005 | 150 | 0.060 |
Why?
|
| Sodium | 1 | 2005 | 61 | 0.060 |
Why?
|
| Topotecan | 1 | 2025 | 5 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 141 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2025 | 71 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2025 | 99 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 488 | 0.060 |
Why?
|
| Particle Size | 1 | 2016 | 403 | 0.060 |
Why?
|
| Molecular Docking Simulation | 1 | 2025 | 83 | 0.060 |
Why?
|
| Patient Selection | 3 | 2017 | 453 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 249 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2025 | 665 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 712 | 0.050 |
Why?
|
| Disintegrins | 1 | 2022 | 4 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 7 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Rural Health | 1 | 2002 | 15 | 0.050 |
Why?
|
| Subacute Care | 1 | 2021 | 9 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 84 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 930 | 0.050 |
Why?
|
| Iran | 1 | 2020 | 10 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 1384 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2003 | 205 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 854 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 27 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2020 | 9 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 106 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 21 | 0.040 |
Why?
|
| Retina | 1 | 2021 | 119 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2020 | 38 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 324 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 88 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 205 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 157 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 98 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 192 | 0.040 |
Why?
|
| Angiography | 1 | 2019 | 146 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 51 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2018 | 7 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 68 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2020 | 146 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2021 | 314 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 255 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 262 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 345 | 0.040 |
Why?
|
| Argentina | 1 | 2017 | 6 | 0.040 |
Why?
|
| North America | 1 | 2017 | 115 | 0.040 |
Why?
|
| Venules | 1 | 1997 | 8 | 0.040 |
Why?
|
| Patient Admission | 1 | 2019 | 185 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 63 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2017 | 40 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2020 | 251 | 0.040 |
Why?
|
| Latin America | 1 | 2017 | 15 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 353 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2017 | 44 | 0.030 |
Why?
|
| Algorithms | 2 | 2016 | 1002 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 222 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 406 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 13 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 142 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 792 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2016 | 57 | 0.030 |
Why?
|
| Embolectomy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 454 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2006 | 179 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2009 | 2362 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 793 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 569 | 0.030 |
Why?
|
| Observer Variation | 2 | 2006 | 203 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 391 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 546 | 0.030 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 77 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 892 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 118 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2118 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 119 | 0.030 |
Why?
|
| Health Education | 1 | 2015 | 184 | 0.030 |
Why?
|
| Critical Illness | 1 | 2017 | 341 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2014 | 137 | 0.030 |
Why?
|
| Rats | 2 | 2006 | 1918 | 0.030 |
Why?
|
| Pupil | 1 | 2011 | 12 | 0.020 |
Why?
|
| Paresis | 1 | 2010 | 15 | 0.020 |
Why?
|
| Confusion | 1 | 2010 | 15 | 0.020 |
Why?
|
| Plasmapheresis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Antithyroid Agents | 1 | 2010 | 18 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2010 | 32 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 172 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 121 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2505 | 0.020 |
Why?
|
| Tadalafil | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Ferrocyanides | 1 | 2006 | 1 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 51 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2006 | 29 | 0.020 |
Why?
|
| Anisotropy | 1 | 2006 | 59 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2006 | 132 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 324 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2006 | 143 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 90 | 0.020 |
Why?
|
| Axons | 1 | 2006 | 120 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 71 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 197 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2006 | 177 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2006 | 217 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 685 | 0.010 |
Why?
|
| Decision Making | 1 | 2008 | 394 | 0.010 |
Why?
|
| Stem Cells | 1 | 2006 | 258 | 0.010 |
Why?
|
| Nervous System | 1 | 2004 | 69 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 309 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 639 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 943 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 474 | 0.010 |
Why?
|
| Ontario | 1 | 2002 | 44 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 149 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2002 | 113 | 0.010 |
Why?
|
| Transportation of Patients | 1 | 2002 | 43 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 422 | 0.010 |
Why?
|
| Neurons | 1 | 2006 | 862 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2087 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 19768 | 0.010 |
Why?
|